23:13 , Sep 24, 2018 |  BC Extra  |  Company News

Gilead targets Medicaid with launch of HCV generics

Gilead Sciences Inc. (NASDAQ:GILD) hopes a plan to launch authorized generics of two HCV drugs will lower out-of-pocket costs for patients and increase its share in the Medicaid population. But the head of Medicaid Health...
20:38 , Sep 21, 2018 |  BioCentury  |  Politics, Policy & Law

Filling the rebate void

HHS’s proposal to eliminate drug rebates should have the intended consequence of increasing transparency into drug pricing in the short term. But the long view is that value-based pricing or alternative co-pay agreements will do...
00:53 , Sep 15, 2018 |  BioCentury  |  Politics, Policy & Law

Debating diagnostics

Instead of perpetuating a decades-old dispute about whether FDA can and should regulate laboratory-derived tests, the agency and test makers have moved on to conversations about how FDA should do so, and from threats of...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
18:28 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Sequoia China leads seed round for next-gen T cell therapy play

RootPath Inc. (Cambridge, Mass.) raised on Aug. 30 $7 million in a seed round led by Sequoia China. Fellow new investors Volcanics Venture, Baidu Ventures and Nest.Bio Ventures also participated. Co-founder and CEO Xi Chen told...
11:00 , Aug 30, 2018 |  BC Extra  |  Financial News

Sequoia China leads seed round for next-gen T cell therapy play

RootPath Inc. (Cambridge, Mass.) raised $7 million in a seed round led by Sequoia China. Fellow new investors Volcanics Venture, Baidu Ventures and Nest.Bio Ventures also participated. Co-founder and CEO Xi Chen told BioCentury the funding...
18:33 , Aug 29, 2018 |  BC Innovations  |  Translation in Brief

Accelerated healing

In a Science Translational Medicine paper published last month, an NIH team showed SRY (sex determining region Y)-box 2 (SOX2) and paired-like homeodomain 1 (PITX1) can activate wound healing, and is now evaluating the transcription...
06:14 , Aug 10, 2018 |  BC Week In Review  |  Company News

CVS earns less off rebates than the Street thought

CVS Health Corp. (NYSE:CVS) reported lower-than-expected contribution of retained rebates to its 2Q18 earnings and drew closer to completing its acquisition of Aetna Inc. (NYSE:AET) -- a move expected to cut its healthcare costs. CVS revealed...
22:06 , Aug 9, 2018 |  BC Extra  |  Company News

CVS earns less off rebates than the Street thought

CVS Health Corp. (NYSE:CVS) reported lower-than-expected contribution of retained rebates to its 2Q18 earnings and drew closer to completing its acquisition of Aetna Inc. (NYSE:AET) -- a move expected to cut its healthcare costs. CVS revealed...
03:14 , Aug 8, 2018 |  BC Extra  |  Politics & Policy

CMS opens private-sector negotiation to Medicare Part B

CMS unveiled details of a policy under the Trump administration's drug pricing blueprint that will apply private-sector negotiation tools into some Medicare Part B plans and create competition between Part B and D drugs. Plans...